AAPL

TSLA

AMZN

META

AMD

NVDA

PEP

COST

ADBE

GOOG

AMGN

HON

INTC

INTU

NFLX

ADP

SBUX

MRNA

Markets

Alteogen Stock Up On Upto $579 Mln Deal With Biogen For Hybrozyme-Based Subcutaneous Biologics

March 26, 2026 — 09:05 am EDT

Written by

RTTNews.com for

RTTNews->

(RTTNews) - Shares of Alteogen Inc. (196170.KQ) gained around 6 percent on Thursday's trading in South Korea after the biopharma company announced that it has entered into an exclusive license agreement with Biotechnology company Biogen, Inc. (BIIB) for the development and commercialization of Hybrozyme-based Subcutaneous Biologics in up to $579 million deal.

In South Korea, Alteogen shares closed Thursday's regular trading at 381,000 won, up 6.28%.

In pre-market activity on the Nasdaq, Biogen shares were losing around 2 percent to trade at $185.36.

Under the deal, Biogen gains rights to develop and commercialize subcutaneous or SC formulations for two products utilizing ALT-B4 (berahyaluronidase alfa) powered by Alteogen's Hybrozyme technology.

ALT-B4 (berahyaluronidase alfa) is a proprietary recombinant human hyaluronidase developed using Alteogen's Hybrozyme platform technology.

Alteogen will receive an upfront payment of $20 million and is eligible to receive an additional $10 million upon initiation of development of the second product.

In addition, the company is eligible to receive up to $549 million in development, regulatory, and sales milestone payments for the two products combined.

Following commercialization, Alteogen will also be entitled to receive royalties based on net sales.

Under the agreement, Biogen also holds an option to develop a third product.

For More Such Health News, visit rttnews.com

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.